^
Association details:
| Biomarker: | ERBB3 amplification + ERBB3 mutation |
|---|---|
| Cancer: | Gallbladder Cancer |
| Drug: | Herceptin (trastuzumab) (HER2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Anti-Her2neu directed therapy in advanced gall bladder cancer: A prospective, multicenter experience from India.
Published date:
05/25/2020
Excerpt:
Five patients were positive for Her3 mutation and/or amplification….At a median follow-up of 6.8 months, median PFS was 4.1 months for chemotherapy only (n = 85) and 9.7 months for trastuzumab with chemotherapy (n = 21) (HR 0.22; P < 0.05). The median OS was 14 and 6 months in patients with or without trastuzumab-based therapy (HR 0.08 P = 0.001), respectively.
Secondary therapy:
Chemotherapy
DOI:
10.1200/JCO.2020.38.15_suppl.e16682
